Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pharmacyclics, Inc.    PCYC   US7169331060


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pharmacyclics Inks Agreement With Novo Nordisk for Molecule Inhibitor

10/09/2012 | 06:25pm US/Eastern
   By Kristin Jones 

Pharmacyclics Inc. (>> Pharmacyclics, Inc.) has inked an agreement with Novo Nordisk A/S (NVO, NOVO-B.KO) giving the Danish insulin producer rights to certain uses of its Factor VIIa molecule inhibitor, according to a regulatory filing.

Pharmacyclics shares rose 3.75% to $67.20 in after-hours trading. Through the close, the stock had more than doubled in the past six months.

Under the terms of the agreement, Novo Nordisk will acquire the world-wide rights to PCI-27483 for specific noncancer-related uses. The Danish company plans to use it as an excipient in an unnamed product within its biopharmaceutical unit.

An excipient is generally an inactive ingredient used to carry or to add a certain consistency to a drug.

Pharmacyclics has been developing PCI-27483 to inhibit the intracellular signaling involved in tumor growth and to thwart the blood clots that afflict some cancer patients.

The biopharmaceutical company expects to receive an upfront payment of $5 million, as well as up to $55 million based on the achievement of certain development, regulatory and sales milestones. It also will receive royalties on sales of Novo Nordisk products that use PCI-27483.

Novo Nordisk's American depositary shares closed Tuesday at $161.38 and were unchanged after hours. The ADS are up 40% so far this year.

Write to Kristin Jones at

Subscribe to WSJ:

Stocks mentioned in the article : Pharmacyclics, Inc.
React to this article
Latest news on PHARMACYCLICS, INC.
4d ago PHARMACYCLICS : Assigned Patent
7d ago PHARMACYCLICS : Named 2014 Outstanding Company by BayBio
12/11 PHARMACYCLICS : Regulation FD Disclosure, Financial Statements and Exhibits (for..
12/10 PHARMACYCLICS : New IMBRUVICA® ibrutinib Application Accepted by European Medici..
12/10 PHARMACYCLICS : J&J -IMBRUVICA (ibrutinib) Long-term Follow-up Data in Patients ..
12/09 PHARMACYCLICS : Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates S..
12/09 PHARMACYCLICS : Assigned Patent
12/08 PHARMACYCLICS : IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability o..
12/08 PHARMACYCLICS : IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows ..
12/06 PHARMACYCLICS : IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma
Duration : Period :
Pharmacyclics, Inc. Technical Analysis Chart | PCYC | US7169331060 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes